The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase
Open accessAbstract
The NRF2 transcription factor controls a cell stress program that is implicated in cancer and there is great interest in targeting NRF2 for therapy. We show that NRF2 activity depends on Fructosamine-3-kinase (FN3K)-a kinase that triggers protein de-glycation. In its absence, NRF2 is extensively glycated, unstable, and defective at binding to small MAF proteins and transcriptional activation. Moreover, the development of hepatocellular carcinoma triggered by MYC and Keap1 inactivation depends on FN3K in vivo. N-acetyl cysteine treatment partially rescues the effects of FN3K loss on NRF2 driven tumor phenotypes indicating a key role for NRF2-mediated redox balance. Mass spectrometry reveals that other proteins undergo FN3K-sensitive glycation, including translation factors, heat shock proteins, and histones. How glycation affects their functions remains to be defined. In summary, our study reveals a surprising role for the glycation of cellular proteins and implicates FN3K as targetable modulator of NRF2 activity in cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NRF2 stability and function depend on removal of sugars from the NRF2 protein, triggered by FN3K phosphorylation of sugar residues attached to NRF2's C-terminal domain.
“We know that NRF2 functions depend on removal of sugar adducts by the frutosamine-3-kinase (FN3K).”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [14]
The Discussion section, “NRF2 function requires removal of sugar adducts,” directly supports the citing sentence: FN3K phosphorylates attached sugars to trigger their removal, and NRF2 activity requires FN3K. The expanded claim overgeneralizes the stability finding: the Results section, “Glycation decreases NRF2 stability in KEAP1 proficient cells,” reports reduced stability in KEAP1-wild-type cells but unchanged stability in KEAP1-mutant cells. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · see citing works
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903 · see citing works
In-gel digestion for mass spectrometric characterization of proteins and proteomes
Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,867 · see citing works
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201 · see citing works
Self-citationRappsilber, J., Ishihama, Y., & Mann, M. (2002) · Analytical Chemistry · doi:10.1021/ac026117i · Cited by 2,589 · see citing works
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · see citing works
Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1
Mills, E. L., Ryan, D. G., Prag, H. A., Dikovskaya, D., Menon, D., Zaslona, Z., Jedrychowski, M. P., Costa, A. S. H., Higgins, M., Hams, E., et al. (2018) · Nature · doi:10.1038/nature25986 · Cited by 1,885 · see citing works
Vertebrate protein glycosylation: diversity, synthesis and function
Moremen, K. W., Tiemeyer, M., & Nairn, A. V. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3383 · Cited by 1,681 · see citing works
NRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672 · see citing works
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · see citing works
The emerging role of the Nrf2–Keap1 signaling pathway in cancerPreprint
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,304 · see citing works
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,091 · see citing works
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · see citing works
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · see citing works
Harris, I. S., Treloar, A. E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K. C., Yung, K. Y., Brenner, D., Knobbe-Thomsen, C. B., Cox, M. A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.019 · Cited by 993 · see citing works
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839 · see citing works
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818 · see citing works
Malhotra, D., Portales-Casamar, É., Singh, A., Srivastava, S., Arenillas, D. J., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq212 · Cited by 796 · see citing works
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · see citing works
The Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633 · see citing works
In vivo imaging of glucose uptake and metabolism in tumors
Walker-Samuel, S., Ramasawmy, R., Torrealdea, F., Rega, M., Rajkumar, V., Johnson, S. P., Richardson, S., Gonçalves, M., Parkes, H. G., Årstad, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3252 · Cited by 479 · see citing works
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466 · see citing works
Ortega-Molina, A., Boss, I. W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. (2015) · Nature Medicine · doi:10.1038/nm.3943 · Cited by 438 · see citing works
Self-citationZhang, Q., Ames, J. M., Smith, R. D., Baynes, J. W., & Metz, T. O. (2009) · Journal of Proteome Research · doi:10.1021/pr800858h · Cited by 421 · see citing works
Review: Glycation of human serum albumin
Anguizola, J. A., Matsuda, R., Barnaby, O. S., Hoy, K. S., Wa, C., DeBolt, E., Koke, M., & Hage, D. S. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.07.013 · Cited by 395 · see citing works
Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1
Reichard, J. F., Motz, G. T., & Puga, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm638 · Cited by 393 · see citing works
Sites of nonenzymatic glycosylation of human hemoglobin A.
Shapiro, R., McManus, M., Zalut, C., & Bunn, H. F. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85860-x · Cited by 368 · see citing works
A metabolite-derived protein modification integrates glycolysis with KEAP1–NRF2 signalling
Bollong, M. J., Lee, G., Coukos, J. S., Yun, H., Zambaldo, C., Chang, J. W., Chin, E. N., Ahmad, I., Chatterjee, A. K., Lairson, L. L., et al. (2018) · Nature · doi:10.1038/s41586-018-0622-0 · Cited by 344 · see citing works
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Takahashi, N., Chen, H., Harris, I. S., Stover, D. G., Selfors, L. M., Bronson, R. T., Raedt, T. D., Cichowski, K. M., Welm, A. L., Mori, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.001 · Cited by 277 · see citing works
Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259 · see citing works
Satoh, H., Moriguchi, T., Takai, J., Ebina, M., & Yamamoto, M. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4499 · Cited by 251 · see citing works
p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer
Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F., Kastenhuber, E. R., Weissmueller, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.051 · Cited by 227 · see citing works
Self-citationPost-translational modification and regulation of actin
Terman, J. R., & Kashina, A. S. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.10.009 · Cited by 224 · see citing works
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C. N., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.010 · Cited by 200 · see citing works
Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks
Galligan, J. J., Wepy, J. A., Streeter, M. D., Kingsley, P. J., Mitchener, M. M., Wauchope, O. R., Beavers, W. N., Rose, K. L., Wang, T., Spiegel, D. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802901115 · Cited by 190 · see citing works
Analysis and prediction of mammalian protein glycation
Johansen, M. B., Kiemer, L., & Brunak, S. (2006) · Glycobiology · doi:10.1093/glycob/cwl009 · Cited by 189 · see citing works
Reversible histone glycation is associated with disease-related changes in chromatin architecture
Zheng, Q., Omans, N. D., Leicher, R., Osunsade, A., Agustinus, A. S., Finkin-Groner, E., D’Ambrosio, H. K., Liu, B., Chandarlapaty, S., Liu, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09192-z · Cited by 186 · see citing works
Guanine glycation repair by DJ-1/Park7 and its bacterial homologs
Richarme, G., Cai-ling, L., Mihoub, M., Abdallah, J., Léger, T., Joly, N., Liébart, J.-C., Jurkunas, U. V., Nadal, M., Bouloc, P., et al. (2017) · Science · doi:10.1126/science.aag1095 · Cited by 174 · see citing works
Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors.
McKearn, J. P., McCubrey, J. A., & Fagg, B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.21.7414 · Cited by 169 · see citing works
Frank, R., Scheffler, M., Merkelbach‐Bruse, S., Ihle, M. A., Kron, A., Rauer, M., Ueckeroth, F., König, K., Michels, S. Y. F., Fischer, R. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3416 · Cited by 167 · see citing works
Bai, X., Chen, Y., Hou, X., Huang, M., & Jin, J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1197239 · Cited by 159 · see citing works
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma
Banito, A., Li, X., Laporte, A. N., Roe, J., Sánchez-Vega, F., Huang, C., Dancsok, A. R., Hatzi, K., Chen, C.-C., Tschaharganeh, D. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.018 · Cited by 158 · see citing works
Self-citationNokin, M., Durieux, F., Peixoto, P., Chiavarina, B., Peulen, O., Blomme, A., Turtoï, A., Costanza, B., Smargiasso, N., Baiwir, D., et al. (2016) · eLife · doi:10.7554/elife.19375 · Cited by 137 · see citing works
Glycoscience: Biology and Medicine
(2015) · doi:10.1007/978-4-431-54841-6 · Cited by 129 · see citing works
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129 · see citing works
Self-citationProtein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression
Lehrbach, N. J., Breen, P. C., & Ruvkun, G. (2019) · Cell · doi:10.1016/j.cell.2019.03.035 · Cited by 125 · see citing works
Nrf2 is a potential therapeutic target in radioresistance in human cancer
Zhou, S., Ye, W., Shao, Q., Zhang, M., & Liang, J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.09.001 · Cited by 115 · see citing works
Hunter, S. J., Boyd, A. C., O'Harte, F. P. M., McKillop, A. M., Wiggam, M. I., Mooney, M. H., McCluskey, J. T., Lindsay, J. R., Ennis, C. N., Gamble, R., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.2.492 · Cited by 111 · see citing works
Satoh, H., Moriguchi, T., Saigusa, D., Baird, L., Yu, L., Rokutan, H., Igarashi, K., Ebina, M., Shibata, T., & Yamamoto, M. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1584 · Cited by 102 · see citing works
Targeted Deletion of Nrf2 Reduces Urethane-Induced Lung Tumor Development in Mice
Bauer, A. K., Cho, H., Miller‐DeGraff, L., Walker, C., Helms, K. L., Fostel, J. M., Yamamoto, M. P., & Kleeberger, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026590 · Cited by 95 · see citing works
E2f8 mediates tumor suppression in postnatal liver development
Kent, L. N., Rakijas, J. B., Pandit, S. K., Westendorp, B., Chen, H.-Z., Huntington, J. T., Tang, X., Bae, S., Srivastava, A., Senapati, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85506 · Cited by 95 · see citing works
Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance
Kang, K. A., & Hyun, J. W. (2017) · Toxicological Research · doi:10.5487/tr.2017.33.1.001 · Cited by 92 · see citing works
Enzymatic repair of Amadori products
SCHAFTINGEN, E. V., Collard, F., Wiame, E., & Veiga‐da‐Cunha, M. (2010) · Amino Acids · doi:10.1007/s00726-010-0780-3 · Cited by 91 · see citing works
Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis
Ngo, H. K. C., Kim, D., Cha, Y., Na, H., & Surh, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3538 · Cited by 88 · see citing works
Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses
Torrente, L., Sanchez, C., Moreno, R., Chowdhry, S., Cabello, P., Isono, K., Koseki, H., Honda, T., Hayes, J. D., Dinkova‐Kostova, A. T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.221 · Cited by 87 · see citing works
Venkatraman, J., Aggarwal, K., & Balaram, P. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00036-9 · Cited by 85 · see citing works
Increased protein glycation in fructosamine 3-kinase-deficient mice
Veiga‐da‐Cunha, M., Jacquemin, P., Delpierre, G., Godfraind, C., Théate, I., Vertommen, D., Clotman, F., Lemaigre, F. P., Devuyst, O., & SCHAFTINGEN, E. V. (2006) · Biochemical Journal · doi:10.1042/bj20060684 · Cited by 84 · see citing works
Zanotto‐Filho, A., Masamsetti, V. P., Loranc, E., Tonapi, S. S., Gorthi, A., Bernard, X., Gonçalves, R. M., Moreira, J. C. F., Chen, Y., & Bishop, A. J. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0271 · Cited by 68 · see citing works
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2
Morales‐González, J. A., Morales‐González, Á., & Madrigal‐Santillán, E. (2016) · InTech eBooks · doi:10.5772/62743 · Cited by 62 · see citing works
[7] Measurement of nonenzymatic protein glycosylation
Flückiger, R., & Gallop, P. M. (1984) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(84)06009-2 · Cited by 56 · see citing works
Fortpied, J., Maliekal, P., Vertommen, D., & SCHAFTINGEN, E. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513208200 · Cited by 48 · see citing works
Histone Acetylation near the Nucleosome Dyad Axis Enhances Nucleosome Disassembly by RSC and SWI/SNF
Chatterjee, N., North, J. A., Dechassa, M. L., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00441-15 · Cited by 47 · see citing works
Gly-PseAAC: Identifying protein lysine glycation through sequences
Xu, Y., Li, L., Ding, J., Wu, L., Mai, G., & Zhou, F. (2016) · Gene · doi:10.1016/j.gene.2016.11.021 · Cited by 47 · see citing works
NRF2 Rewires Cellular Metabolism to Support the Antioxidant Response
Lin, T.-Y., Cantley, L. C., & DeNicola, G. M. (2016) · InTech eBooks · doi:10.5772/65141 · Cited by 43 · see citing works
Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture
Abdel‐Wahab, Y. H. A., O'Harte, F. P. M., Barnett, C. R., & Flatt, P. R. (1997) · Journal of Endocrinology · doi:10.1677/joe.0.1520059 · Cited by 41 · see citing works
Marotta, E., Lapolla, A., Fedele, D., et al. (2003) · Journal of Mass Spectrometry · doi:10.1002/jms.431 · Cited by 35 · see citing works
Wang, M., Li, G., Yang, Z., Wang, L., Zhang, L., Wang, T., Zhang, Y., Zhang, S., Han, Y., & Jia, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14097 · Cited by 34 · see citing works
Glycated hemoglobin is a marker of diabetes and CVD risk
Wareham, N. J., & Pfister, R. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.84 · Cited by 21 · see citing works
Hu, W., & Liu, W. (2010) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-010-9274-6 · Cited by 21 · see citing works
Kramer, R. A., Soble, M. J., Howes, A. E., & Montoya, V. P. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90308-8 · Cited by 19 · see citing works
Keap1 mutations in lung cancer patients
Sasaki, H., Suzuki, A., Shitara, M., Okuda, K., Hikosaka, Y., Moriyama, S., Yano, M., & Fujii, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1427 · Cited by 18 · see citing works
Takahashi, M. (2014) · Springer eBooks · doi:10.1007/978-4-431-54836-2_182-1 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
NRF2, a Transcription Factor for Stress Response and Beyond
He, F., Ru, X., & Wen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134777 · Cited by 1,820 · see citing works
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27 · see citing works
Self-citationAdverse Effects of Nrf2 in Different Organs and the Related Diseases
Jin, X., Chen, L., Yang, Y., Tan, R., & Jiang, C. (2025) · Antioxidants & Redox Signaling · doi:10.1089/ars.2024.0586 · Cited by 11 · see citing works
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 10 · see citing works
“…of suicide genes, such as DcK or HSv-tK, to transcriptional reporters enabled the identification of genes essential for diverse signaling pathways (Sanghvi et al. 2019; lampson et al. 2024). this demonstrates the scalability and versatility of this positive-selection approach for both functional…”
- Authors
- Sanghvi, V. R., Leibold, J., Mina, M., Mohan, P., Berishaj, M., Li, Z., Miele, M. M., Lailler, N., Zhao, C., de Stanchina, E., Viale, A., Akkari, L., Lowe, S. W., Ciriello, G., Hendrickson, R. C., & Wendel, H.-G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- SIB Swiss Institute of Bioinformatics (CH)
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Wendel, Hans-Guido
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 178
- Issue
- 4
- Pages
- 807-819.e21
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6693658
- OpenAlex
- W2968887911
- Cited by
- 155
- References
- 73
- Citations by year
- 2026: 19 · 2025: 16 · 2024: 30 · 2023: 19 · 2022: 23 · 2021: 22 · 2020: 24 · 2019: 2
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- Starr Foundation
- Leukemia and Lymphoma Society
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Nrf2, fructosamine-3-kinase, protein glycation, oncogenic signaling, hepatocellular carcinoma, c-Myc, Keap1, N-acetylcysteine, redox homeostasis, transcriptional activation, heat shock proteins, translation factors, cancer therapy targets
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Animals, Female, Glucose, Glycosylation, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Mice, Inbred C57BL, Mice, Nude, Transduction, Genetic, Proto-Oncogene Proteins c-myc, Mice, SCID, Mice, Inbred NOD, Phosphotransferases (Alcohol Group Acceptor), NF-E2-Related Factor 2, Mice, Gene Knockdown Techniques, Hep G2 Cells, HEK293 Cells, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
